Objectives: A study was conducted to evaluate the occurrence and characterization of extended-spectrum b-lactamases (ESBLs) among blood isolates of Proteus mirabilis collected over a 4 year period in Hong Kong.
Introduction
The emergence of extended-spectrum b-lactamases (ESBLs) in Gram-negative bacteria has become a major public health concern. It is clinically important to detect and specifically target ESBL because ESBL-producers may be clinically resistant to many b-lactams including the penicillins, aztreonam and oxyiminocephalosporins. 1 Among the Enterobacteriaceae, the TEM-and SHV-derived ESBLs are often the predominant enzyme types among enterobacteria with an ESBL phenotype. 2 In some South American countries, however, the CTX-M enzymes instead of the TEM-and SHV-derived enzymes are the predominant ESBL types. 3 In a survey of 17 metropolitan public hospitals of Buenos Aires City, a CTX-M-2-related b-lactamase was found in 26 of 37 (70.3%) ESBL-producing enterobacteria. 4 In Southeast Asia, a variety of CTX-M enzymes have been observed including: in mainland China, CTX-M-1, -3, -9, -13 and -14; 5 -8 in Taiwan, CTX-M-3, -14 and -15; 9 -11 in Hong Kong, CTX-M-2, -9, -13, -14 and -24; 12 in Korea, CTX-M-14; 13 and in Japan, CTX-M-2, -3, -14, -M15, Toho-1 and Toho-2. 3, 14, 15 In some of the above reports, the findings further indicated that the CTX-M group b-lactamases were already the predominant ESBL type in some Asian hospitals. In mainland China, one survey at the Peking Union Medical College hospital in 1999 identified CTX-M-3 among 19 of 27 (70.4%) ESBL-producing Enterobacteriaceae including three of five Escherichia coli, 11 of 17 Klebsiella pneumoniae and all of three Enterobacter cloacae and two Citrobacter freundii. 6 This compared with another study in 1999 at the Huashan hospital that CTX-M-1 group was found in 13 of 58 (22.4%) E. coli and 41 of 81 (50.6%) K. pneumoniae. 7 In Taiwan, at the National Cheng Kung University Hospital, a study of 1210 E. coli clinical isolates in 1999 identified 18 ESBL-producers, of which 10 isolates were found to harbour CTX-M-3. 11 In Hong Kong, a study of 139 enterobacters in 2000 to 2002 by our group revealed CTX-M enzymes in five of nine unrelated ESBL producers. 12 Among Proteus mirabilis, strains harbouring CTX-M enzymes were previously observed in Italy (CTX-M-1), 16 France (CTX-M-1 and -20), 16 Brazil (CTX-M-8) 17 and Argentina (CTX-M-2). 4, 18 Information on the prevalence of ESBL as well as the occurrence of CTX-M enzymes among P. mirabilis in Asian countries is lacking. Therefore, this study was conducted to evaluate the occurrence and characterization of ESBLs in blood isolates of P. mirabilis collected over a 4 year period in Hong Kong.
Materials and methods
Bacterial strains, susceptibility testing and patient data Blood isolates of P. mirabilis isolated from 1999 to 2002 in eight hospitals in Hong Kong were evaluated. The eight hospitals include one 1400 bed university teaching hospital and seven district general hospitals (130 -700 beds). The teaching hospital (QMH) provides acute care for all the major specialties for $ 12% of the 6.5 million population in Hong Kong, and has specialized centres for management of bone marrow, renal and liver transplant patients. Over the study period, there were altogether 114 consecutive blood isolates. By the first isolate per patient method, 19 15 repeat isolates from the same patients were eliminated and 99 non-duplicate isolates were included in this study. Only one isolate from each patient was included. The numbers of isolates from each year were as follows: The VITEK GNI system (bioMérieux Vitek Inc., Hazelwood, MO, USA) was used for bacterial identification. Antibiotic susceptibilities to amoxicillin/clavulanic acid, piperacillin/tazobactam, cefoperazone/sulbactam, cefoxitin, ceftazidime, cefotaxime, ceftriaxone, cefepime, imipenem, gentamicin, amikacin, ciprofloxacin, chloramphenicol, sulfamethoxazole, trimethoprim, co-trimoxazole and tetracycline were tested by the disc diffusion method using Mueller -Hinton agar (Oxoid, Basingstoke, UK) and interpreted according to the NCCLS. 20 All antibiotic discs were obtained commercially (BBL, Becton Dickinson, Cockeysville, MD, USA). For the ESBL-producing strains, the patient records were reviewed for the following data and risk factors: date of isolation, date of admission, age, gender, old age home residence, type of infection, co-morbidity and previous hospitalization. Co-morbidity was defined as any underlying illness that might increase the risk of infection. Healthcare-associated ESBL cases were empirically defined as patients with an infection identified after 48 h of admission to a hospital; or a history of recent hospitalization in the preceding 6 weeks, or residence in an old age home. Cases that had none of the above were classified as community-associated. 1 
Detection of ESBL
Production of ESBL in the strains was screened by the double-disc synergy test. 21 Two agar plates were inoculated as described for the standard disc diffusion test. In each plate, four 30 mg discs (ceftazidime, cefpodoxime, ceftriaxone and cefepime) were placed at interdisc distances (centre to centre) of 25 or 30 mm away from an amoxicillin/clavulanic acid disc (20/10 mg). A clear extension of the edge of the inhibition zone towards the disc containing clavulanic acid was interpreted as positive for ESBL production.
Molecular analysis of mechanism of resistance
A PCR and sequencing strategy was used to characterize enzymes related to the TEM, SHV and CTX-M families using primers previously described. 16, 22, 23 Template DNA preparation and PCR amplifications were carried out as described previously in a final volume of 50 mL with 2 mL of template DNA and 0.4 mM of each primer. PCR amplification was performed in a Perkin-Elmer 9600 thermal cycler. 12 Amplification parameters involved 30 cycles with 1 min at 958C, 45 s at 558C and 45 s at 728C. A final elongation was carried out at 728C for 10 min. The amplicons generated by the primers specific for bla TEM , bla SHV , or bla CTX-M were sequenced directly after purification with the High Pure PCR Product Purification kit, as directed by the manufacturer (Roche Diagnostics, Mannheim, Germany). The primers TEM- 0 -AAA AAT GAT TGA AAG GTG GT-3 0 (position 6285-6304, accession no. AF458080) and the consensus reverse MA2. 16 All amplicons were generated and sequenced at least twice by automated PCR cycle sequencing with the BigDye dideoxynucleotide chain termination method in an ABI PRISMe 377 Genetic Analyzer (Perkin-Elmer, Foster City, CA, USA). Amino acids in the b-lactamases were numbered according to Ambler et al. 25 Positive (E. coli J53 Azi r with encoded bla TEM-1 , bla SHV-1 and bla CTX-M-1, 2 and 9 ) and negative (E. coli J53 Azi r and water) controls were used in all reactions.
Presence of class I, II and III integrons in the strains were evaluated by PCR using primers published previously. 26, 27 Isoelectric focusing (IEF)
Analytic IEF was performed in ampholine gel (pH 3.0 to 10.0; Pharmacia, Hong Kong, China) using lysozyme-based enzyme extract on an HE 950 isoelectric focusing apparatus (Hoefer Scientific Instruments, CA, USA). 28 Isolates were examined which had an ESBL phenotype in the screening tests but where the enzyme type remained unidentified by the PCR and sequencing strategies. The pI value of each enzyme was determined by spreading nitrocefin on the gel surface. 29 Preparations from standard strains known to harbour TEM-1, TEM-8, SHV-4 and SHV-5 were used as markers. ESBL activity was detected by the substrate gel overlay method using cefotaxime at 1 mg/L and Escherichia coli ATCC 25922 as an indicator.
Antibiotic resistance transfer and plasmid content analysis
Plasmid DNA was extracted by two methods. Small plasmids (less than 10 -20 kb) were extracted by the QIAprep Spin Miniprep Kit (Qiagen, Hong Kong) and analysed by conventional gel electrophoresis in accordance with manufacturer's instructions. For detecting large plasmids, bacterial cells were embedded in agarose plugs and disrupted by alkaline lysis. Subsequently, the plasmids were converted to the linear forms by incubation with Aspergillus oryzae S1 nuclease (Sigma Chemical Co., St Louis, MO, USA) and were sized by pulsed-field gel electrophoresis (PFGE) as previously described. 30 Filter conjugation was carried out in filters with E. coli J53Azi r as the recipient. 28 Cultures of the donor and recipient were collected on sterilized filters (Whatman International Ltd, Maidstone, UK) and the filter was incubated on the surface of an LB agar plate overnight. Inhibition of swarming was achieved by incubation at 308C. 31 Transconjugants were selected on Trypticase soy agar (TSA) plates containing sodium azide (150 mg/L; Sigma Chemical Co.) for counterselection and cefotaxime (0.5 or 1 mg/L; Sigma Chemical Co.) to select for plasmid-encoded resistance.
Epidemiological typing
All strains were typed by the Dienes test using the procedure described by Skirrow. 32 Conventional 5% horse blood agar plates were used. Discrimination of unique strains is based on the mutual inhibition of two different strains as they swarm towards each other on the agar surface. Initially, seven strains were spot inoculated onto one 9 cm plate to allow reading of 12 combinations. Inoculated plates were incubated at 358C for 18 to 24 h before reading. The presence of mutual inhibition lines (i.e. Dienes lines) between two isolates indicates that the isolates were unrelated and represented distinct Dienes types. On the other hand, strains were assigned to the same type if Dienes lines were absent. Each pair of compatible reactions was always confirmed by repeat testing. In the confirmatory testing, each agar plate was spot inoculated with one pair of isolates. Slowly swarming isolates were incubated for up to 48 h. If their spreading growths had not met, the test was repeated on a plate containing a thicker layer of agar. In this manner, each isolate was tested against all other isolates. The letters A, B, C and so on were assigned for each distinct Dienes type.
The subset of ESBL-producing strains was examined further by PFGE. Not I (Amersham Pharmacia Biotech, Little Chalfont, UK) was used for macrorestriction digestion of genomic DNA. The fragments were resolved in 1% gel in a CHEP Mapper XA (Bio-Rad) for 22 h at 6 V/cm gradient and an included angle of 1208. The switching time ramped from an initial 2.2 s to a final 54.2 s.
Statistical analysis
The Chi-square, Fisher's exact or Student's t-test was used for statistical analysis. A P value of <0.05 was considered significant. For the purpose of analysis, non-susceptible including both intermediate and resistant categories was used in the calculation.
Nucleotide sequence accession number
The following b-lactamase genes have been submitted to the GenBank nucleotide sequence database under the following accession numbers: AY874537 (bla TEM-11 , strain 217C5), AY870398 (bla CTX-M-13 , strain 209A4), AY870399 (bla CTX-M-14 , strain 255I3).
Results

Frequency of ESBL production and antimicrobial susceptibility
The double-disc synergy test identified 13 (13.1%) isolates as ESBL-producers and 86 (86.9%) isolates as ESBL-non-producers. In terms of year of isolation, the ESBL rates were: 0% (0/26) in 1999, 0% (0/15) in 2000, 18.5% (5/27) in 2001 and 25.8% (8/31) in 2002. On the basis of the inhibition zone diameters alone, one of the 13 ESBL-producing isolates was susceptible to cefotaxime, six were susceptible to ceftriaxone ( > _ 21 mm) and 11 were susceptible to ceftazidime ( > _ 18 mm). In order to evaluate the effectiveness of extending the NCCLS E. coli and Klebsiella spp. ESBL breakpoints for initial screening of P. mirabilis, interpretation of the disc results for cefotaxime, ceftriaxone and ceftazidime were tabulated against the ESBL production status (not shown). The sensitivity and specificity of the NCCLS screening criteria were as follows: 92.3% and 100% for cefotaxime, 92.3% and 100% for ceftriaxone, and 15.3% and 100% for ceftazidime, respectively. One isolate (strain 217C5) escaped detection by all three discs (inhibition zone 23 mm for ceftazidime, 31 mm for cefotaxime and 35 mm for ceftriaxone).
Susceptibility of the isolates according to ESBL production is shown in Table 1 . All isolates were susceptible to cefoxitin, suggesting that there were no AmpC-like enzymes. Strains with ESBL were more likely than those without to have resistance to gentamicin, tobramycin and ciprofloxacin. The non-susceptible rates for chloramphenicol, and co-trimoxazole were similar for the two groups. Multidrug resistance phenotypes for the non-b-lactam antibiotics were high in both groups. Most ESBL-producing strains were intermediate or resistant to ampicillin/sulbactam and amoxicillin/clavulanate while all were susceptible to piperacillin/tazobactam. All isolates were susceptible to amikacin and the two carbapenems.
Characteristics of the ESBL-producing strains
All ESBL-producing strains were isolated from patients with healthcare-related infections. All 13 patients had one or more underlying diseases such as stroke (n = 4), dementia (n = 2), diabetes mellitus (n = 2) and chronic lung disease (n = 2). Nine patients were residents in old age homes. In most patients (9 of 13), the source of bacteraemia was urinary catheter-related infection. The b-lactamase-specific PCR and sequencing revealed the following ESBL enzymes (Table 2) : CTX-M-13 (n = 8), CTX-M-14 (n = 3), SHV-5 (n = 2), and TEM-11 (n = 1). In addition, TEM-2 was found in nine isolates and TEM-1b in one isolate. The gene encoding the TEM-11 had nucleotide sequences (including C at 226, A at 317, G at 346, T at 436, G at 604, C at 682 and A at 925 according to Sutcliffe numbering) that were characteristic of the bla TEM in Tn1 and differed from TEM-2 in Arg-164 (CGT) being replaced by His-164 (CAT). One strain had an unidentified ESBL with a pI of 7.5 in addition to a TEM1b (pI 5.4). In all the strains with a bla TEM , the strong promoter Pa/Pb was found. Class I and class II integrons were detected in 10 and two isolates, respectively. No class III integron was found.
All 11 strains with a bla CTX-M could be amplified with the forward primer ISEcpU1 and the reverse CTX-M consensus primer, MA2. Sequencing of the PCR products revealed a right inverted repeat (IRR) and a À10 putative promoter region in all the strains. For the three strains producing CTX-M-14, there was a 42 bp interval between the IRR and the start codon of bla CTX-M . The strains producing CTX-M-13 had an additional 120 bp insertion to the right of the IRR.
Epidemiological typing of strains
Seven isolates did not produce sufficient swarming on blood agar surface and were not typeable in the Dienes test. The remaining 92 isolates constituted 54 different Dienes types (A to BB). The distribution of the Dienes types according to ESBL status is shown in Table 3 . Fifty-seven formed 13 clusters of 2 to 11 isolates each. There was only one isolate for the each of the remaining 41 Dienes types. The 13 ESBL-producing isolates fell into five Dienes types: nine isolates for Dienes type A and one each for Dienes type B to E. Further analysis of the 13 isolates producing ESBL using PFGE identified five distinct pulsotypes (Table 2 ) and the results were concordant with that obtained by the Dienes test. The nine isolates of Dienes type A had PFGE patterns that were identical or differed by one to four fragments (pulsotype A). The four isolates with Dienes type B to E had four unrelated pulsotypes B to E.
Analysis of the plasmid contents and transfer of antibiotic resistance
Attempts to transfer ESBL phenotype from P. mirabilis to E. coli recipients were unsuccessful despite repeated testing. The ESBL-producing strains had one to four plasmids with size ranging from $ 1.5 to 300 kb (Table 2) . A common 45 kb plasmid was found in all the CTX-M-13-producing strains. The three CTX-M-14-producing strains had plasmids of different sizes.
Discussion
Our data revealed a high prevalence of ESBL among P. mirabilis that caused invasive infection in Hong Kong. Since ESBL screening of P. mirabilis was not routinely performed in the clinical laboratories, the ESBL status for 12 of the 13 For detecting ESBL, screening with both ceftriaxone and ceftazidime was necessary for optimal sensitivity. This is because specific types of ESBLs may preferentially hydrolyse either ceftriaxone (or cefotaxime) or ceftazidime. In this regard, most CTX-M-type enzymes are 'cefotaximases' while many TEM-and SHV-derived ESBLs are 'ceftazidimases'. According to Schwaber et al., 34 ESBL confirmatory testing for the two pairs of discs containing ceftazidime and cefotaxime alone, and in combination with clavulanic acid was useful for a small sample of P. mirabilis. However, the number of ESBL-positive isolates potentially missed by the NCCLS selection criteria remains unknown because they were not tested. Further studies to evaluate the utility of NCCLS guidelines for identifying ESBLs in P. mirabilis are warranted.
The diversity of ESBLs among the 13 P. mirabilis in this study is intriguing. To the best of our knowledge, this is also the first time CTX-M-13, CTX-M-14 and TEM-11 have been found in P. mirabilis. Among our ESBL-producing strains, CTX-M was the major ESBL type. This is in contrast to the situation in other parts of the world in which TEM-type enzymes were the major ESBL type reported in this bacterial species. In P. mirabilis, the first ESBL, TEM-3 was found in a strain isolated in France in 1989. 35 Subsequently, TEM-8, TEM-15, TEM-20, TEM-21, TEM-24, TEM-52, TEM-57, TEM-66, TEM-72, TEM-87 and TEM-92 were described in Europe and mainly in France and Italy. 36 -42 In the United States, TEM-10 was also known to occur in P. mirabilis. 43 In Argentina where the CTX-M enzymes are widespread, one study found that CTX-M was also prevalent among a small sample of P. mirabilis. 4 As was reported previously, 44 our finding indicates that TEM-2 but not TEM-1 was the major penicillinase in P. mirabilis.
The Dienes test is a simple and highly discriminatory tool for epidemiological typing of P. mirabilis, and is easy to perform. In this study, typing by the Dienes test revealed both clonal and multi-clonal spread of the CTX-M enzymes. As Dienes type A included multiple ESBL-as well as non-ESBL-producing strains, it is possible that strains belonging to this type represent a highly successful lineage. Interestingly, five distinct resistance patterns for the non-b-lactam antibiotics can be recognized among the nine ESBL-producing strains that shared the same Dienes type. As different plasmids were seen in the Dienes A isolates, this may indicate variations in plasmid-mediated resistance determinants.
It is known that genes encoding the CTX-M-type enzymes are often found in transferable plasmids and are readily transmissible by conjugation. 3 However, the ESBL phenotype in the strains did not transfer in this study. This may be explained by previous observations that the efficiency of conjugation from P. mirabilis to E. coli is low. 35 In agreement with the association of the CTX-M with integrons, 3 most of our CTX-M-producing strains had one or two integrons.
In conclusion, our data indicate a high prevalence of ESBL among P. mirabilis in Hong Kong and their enzyme types are diverse. Our findings add to the increasing recognition of CTX-M enzymes in Southeast Asia and emphasize the need for enhanced surveillance of ESBL in this species. Non-typeable 0 7 7
